Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Reports outline cancer gene therapy study findings from Marche Polytechnic University
March 18th, 2008
"Hypoxia occurs in most solid tumors as a result of inefficient vascular development and/or abnormal vascular architecture. During hypoxia, HIF-1 alpha acts as the primary transcription factor functioning to activate multiple target genes, including vascular endothelial growth factor (VEGF)," scientists in Ancona, Italy report. "Several studies have demonstrated that in tumors HIF-1 alpha mediates VEGF protein expression at the transcription level. We aimed to establish whether HCT116 colon cancer cell VEGF expression is regulated by HIF-1 levels after transient transfection with a GFP vector encoding the HIF-1 alpha gene. HCT 116 cell VEGF expression were therefore...
Source: Cancer Weekly (2008-03-18)
|
